Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.77 |
| ▸ | MEN1 | O00255 | 5/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.77 |
| ▸ | GAA | P10253 | 1/20 | 0.77 |
| ▸ | GFER | P55789 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 7/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.76 |
| ▸ | USP7 | Q93009 | 3/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | USP10 | Q14694 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2219175 | 0.88 | KMT2A (1.00) | KMT2AMEN1SMN1; SMN2GAAGFER | |
| SCHEMBL2218106 | 0.87 | KMT2A (0.88) | KMT2AMEN1SMN1; SMN2GAAGFER | |
| SCHEMBL2219588 | 0.84 | KMT2A (1.00) | KMT2AMEN1SMN1; SMN2GAAGFER | |
| SCHEMBL2217529 | 0.84 | KMT2A (0.86) | KMT2AMEN1SMN1; SMN2GAAGFER | |
| SCHEMBL2229536 | 0.81 | MAPT (0.89) | KMT2AMEN1SMN1; SMN2GAAGFER | |
| SCHEMBL13822374 | 0.81 | MAPT (0.89) | KMT2AMEN1SMN1; SMN2GAAGFER | |
| SCHEMBL2227633 | 0.81 | MAPT (0.89) | KMT2AMEN1SMN1; SMN2GAAGFER | |
| SCHEMBL2219850 | 0.78 | KMT2A (0.73) | KMT2AMEN1SMN1; SMN2GAAGFER | |
| SCHEMBL14634957 | 0.78 | KMT2A (0.75) | KMT2AMEN1SMN1; SMN2GAAGFER | |
| SCHEMBL2228568 | 0.77 | MAPT (0.72) | KMT2AMEN1SMN1; SMN2GAAGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023521-A1 | NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS | HYBRIGENICS SA (FR) | 2013-01-24 | — | — | US | claimed |
| EP-2523938-A1 | AMIDOACRIDINE DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | Hybrigenics S.A. (FR) | 2012-11-21 | — | — | EP | claimed |
| WO-2011086178-A1 | AMIDOACRIDINE DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | HYBRIGENICS SA (FR) | 2011-07-21 | — | — | WO | claimed |
| US-9328093-B2 | Selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications | HYBRIGENICS SA (FR) | 2016-05-03 | — | — | US | disclosed |
| US-20150072973-A1 | NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS | HYBRIGENICS SA (FR) | 2015-03-12 | — | — | US | disclosed |
| EP-2523938-B1 | Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7 | HYBRIGENICS SA (FR) | 2014-09-03 | — | — | EP | disclosed |
| US-20130023521-A1 | NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS | HYBRIGENICS SA (FR) | 2013-01-24 | — | — | US | disclosed |
| EP-2523938-A1 | AMIDOACRIDINE DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | Hybrigenics S.A. (FR) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011086178-A1 | AMIDOACRIDINE DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | HYBRIGENICS SA (FR) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023521-A1 | NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS | USP7, SENP7, PSMA7 | KMT2A 2349/4885MEN1 4159/4885SMN1; SMN2 2877/4885 |
| US-20150072973-A1 | NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS | USP7, SENP7, PSMA7 | KMT2A 2349/4885MEN1 4159/4885SMN1; SMN2 2877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.